Nordic Life Science 1
Odyssey® M The most sophisticated imager the indu
stry has ever seen Create new research opportunities and follow your discoveries–wherever they lead. Jan Nilsson, CEO, CombiGene • Dozens of assays • Up to 18 channels • Industry-leading resolution BUSINE S S D E A L Get a live, one-on-one tour at: licor.com/odyssey-m-tour Spark Therapeutics with the exclusive world-wide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark. Under the terms of agreement, CombiGene is eligible to receive up to 328.5 million USD excluding royalties, with 8.5 million USD upon signing, up to 50 million USD at preclinical and clinical milestones. CombiGene will also be reimbursed for certain authorized R&D expenses. Upon commercialization, CombiGene is eligible for tiered royalties ranging from the mid-single digits up to low double-digits based on net sales. “This is a momentous day for CombiGene. Together with our partners and with the support of our shareholders and with an important contribution from the EU program Horizon 2020, we have worked long and hard to arrive at this deal with Spark, and I could not be more proud,” says Jan Nilsson, CEO, CombiGene.